Last update: Nov. 25, 2019

Rivaroxaban

Very Low Risk for breastfeeding


Safe. Compatible.
Not risky for breastfeeding or infant.

Direct factor Xa inhibitor, indicated in the prevention of thromboembolism.
Administered orally every 12 to 24 hours.

Its pharmacokinetic data (large volume of distribution and high percentage of protein binding) explain the very small passage to milk observed in four different cases (Saito 2019, Muysson 2019, Wiesen 2016). No problems were observed in an 18-month-old infant whose mother was treated with rivaroxaban from the first postpartum week (Saito 2019).

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Rivaroxaban in other languages or writings:

Group

Rivaroxaban belongs to this group or family:

Tradenames

Main tradenames from several countries containing Rivaroxaban in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 80 - 100 %
Molecular weight 436 daltons
Protein Binding 92 - 95 %
VD 0,7 l/Kg
pKa 13,6 -
Tmax 2 - 4 hours
T1/2 5 - 9 hours
M/P ratio 0,4 -
Theoretical Dose 0,0034 - 0,024 mg/Kg/d
Relative Dose 1,3 - 4,8 %

References

  1. Muysson M, Marshall K, Datta P, Rewers-Felkins K, Baker T, Hale TW. Rivaroxaban Treatment in Two Breastfeeding Mothers: A Case Series. Breastfeed Med. 2019 Sep 18. Abstract
  2. Saito J, Kaneko K, Yakuwa N, Kawasaki H, Yamatani A, Murashima A. Rivaroxaban Concentration in Breast Milk During Breastfeeding: A Case Study. Breastfeed Med. 2019 Dec;14(10):748-751. Abstract
  3. EMA. Rivaroxaban (Xarelto). Drug Summary. 2017 Full text (in our servers)
  4. EMA. Rivaroxabán (Xarelto). Ficha técnica. 2017 Full text (in our servers)
  5. Wiesen MH, Blaich C, Müller C, Streichert T, Pfister R, Michels G. The Direct Factor Xa Inhibitor Rivaroxaban Passes Into Human Breast Milk. Chest. 2016 Jul;150(1):e1-4. Abstract Full text (link to original source) Full text (in our servers)

Total visits

6,184

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM